Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D, van Dam JL, Han Y, Bonsing BA, Busch OR, Festen S, van der Harst E, de Hingh IH, Homs MYV, Kwon W, Lee M, Lips DJ, de Meijer VE, Molenaar IQ, Nuyttens JJ, Patijn GA, van Roessel S, van der Schelling GP, Suker M, Versteijne E, de Vos-Geelen J, Wilmink JW, van Eijck CHJ, van Tienhoven G, Jang JY, Besselink MG, Groot Koerkamp B; Dutch Pancreatic Cancer Group.
Doppenberg D, et al. Among authors: van dam jl, van der schelling gp, van der harst e, van tienhoven g, van eijck chj, van roessel s.
Br J Surg. 2023 Sep 6;110(10):1374-1380. doi: 10.1093/bjs/znad210.
Br J Surg. 2023.
PMID: 37440421
Free PMC article.